Akebia Therapeutics (AKBA) Total Current Liabilities (2016 - 2025)
Akebia Therapeutics (AKBA) has disclosed Total Current Liabilities for 9 consecutive years, with $162.9 million as the latest value for Q4 2025.
- On a quarterly basis, Total Current Liabilities rose 101.37% to $162.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $162.9 million, a 101.37% increase, with the full-year FY2025 number at $162.9 million, up 101.37% from a year prior.
- Total Current Liabilities was $162.9 million for Q4 2025 at Akebia Therapeutics, up from $91.2 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $261.1 million in Q4 2021 to a low of $79.7 million in Q3 2023.
- A 5-year average of $153.4 million and a median of $162.9 million in 2025 define the central range for Total Current Liabilities.
- Peak YoY movement for Total Current Liabilities: plummeted 66.09% in 2023, then skyrocketed 101.37% in 2025.
- Akebia Therapeutics' Total Current Liabilities stood at $261.1 million in 2021, then tumbled by 50.38% to $129.5 million in 2022, then dropped by 22.9% to $99.9 million in 2023, then dropped by 18.98% to $80.9 million in 2024, then surged by 101.37% to $162.9 million in 2025.
- Per Business Quant, the three most recent readings for AKBA's Total Current Liabilities are $162.9 million (Q4 2025), $91.2 million (Q1 2025), and $80.9 million (Q4 2024).